Videos

Expert hematologist/oncologists highlight challenges in staging chronic graft vs host disease and share strategies to optimize cGHVD assessment.

Treatment with fam-trastuzumab deruxtecan-nxki yielded promising patient-reported outcomes in patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to Naoto Ueno, MD, PhD.

Kami J. Maddocks, MD, reviews findings from the SHINE trial comparing ibrutinib plus bendamustine/rituximab vs bendamustine/rituximab alone in newly diagnosed mantle cell lymphoma.

Focusing on second-line treatment options for EGFR-mutated advanced NSCLC, panelists review the use of mobocertinib and amivantamab, respectively.

Experts briefly reflect on optimal frontline treatment strategies for a patient who presents with EGFR-mutated advanced non–small cell lung cancer.

Lori Leslie, MD, explains how CAR T-cell therapy fits into follicular lymphoma treatment sequencing, highlighting data from the ZUMA-5 trial.

Andre Goy, MD, and Andrew Ip, MD, give an overview of the approval of CAR T-cell therapy for mantle cell lymphoma treatment.

Expert panelists consider which factors would push them toward utilizing triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Centering discussion on a patient case of high-volume metastatic CSPC, expert panelists review the option of triplet therapy based on the PEACE-1 trial.

At the 2022 ASCO Annual Meeting, Christine Parseghian, MD, reviewed results from a phase 2 trial assessing efficacy of panitumumab plus or minus trametinib in patients with RAS/BRAF wild-type colorectal cancer and compared EGFR rechallenge strategies with available agents in the third-line setting.

Drs Costa and Fonesca close out their discussion by highlighting the endemic racial disparities in multiple myeloma treatment.

A look at some of the unmet needs in transplant-ineligible multiple myeloma, particularly within the unfit patient population.

Phillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.

After reviewing a clinical scenario of chronic graft vs host disease, panelists consider the importance of different allogeneic transplant types.

Shared insight on treatment approaches toward patients with acute graft vs host disease who experience partial response to frontline therapy.

Angela DeMichele, MD, MSCE, discussed the results of the phase 2 I-SPY2 trial in patients with early breast cancer

Angela DeMichele, MD, MSCE, discussed how the phase 2 I-SPY2 trial in patients with early breast cancer is informing patient therapy decisions in difficult-to-treat situations.

Phillip H. Kuo, MD, PhD, spoke about the future of theragnostic imaging in patients with metastatic castration-resistant prostate cancer.

Centering discussion on a 57-year-old man with advanced NSCLC, panelists consider molecular testing strategies and the subsets of EGFR mutation.

A brief reflection on optimal patient education strategies, specifically regarding biomarker testing, in the setting of non–small cell lung cancer.

Kami J. Maddocks, MD, talks CAR T-cell therapy approvals for the treatment of relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma plus a new treatment supplanting R-CHOP.

Dr Andrew Ip explains the major toxicities of CAR T-cell therapy in patients with large B-cell lymphoma and how to manage them.

Lymphoma physicians from John Theurer Cancer Center comment on the use of CAR T-cell therapy in large B-cell lymphoma and the implications of clinical trial data in this setting.

Shared insight on optimal patient monitoring strategies while administering therapy for metastatic castration-sensitive prostate cancer.

Shared insight on optimal patient monitoring strategies while administering therapy for metastatic castration-sensitive prostate cancer.

In an interview with CancerNetwork®, E. David Crawford, MD, discussed implications from the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer based on findings from the phase 3 ARASENS trial.

An expert describes how he determines treatment duration and discontinuation for transplant-ineligible multiple myeloma in his clinical practice.

Luciano Costa, MD, PhD, discusses his maintenance therapy strategies for patients with transplant-ineligible multiple myeloma.

Cornelis J. A. Punt, MD, PhD, spoke about bevacizumab plus either FOLFOXIRI or FOLFOX/FOLFIRI in patients with unresectable colorectal liver metastases and right-sided or RAS/BRAF-mutant tumors and how these regimens may be used for curative-intent therapy.

Focusing on pharmacologic options, expert panelists review frontline treatment strategies for patients with acute graft vs host disease.